Stock Analiz

BioNTech SE (BNTX) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

BioNTech’s revenue went from $74M in fiscal 2017 to $3.4B in fiscal 2025, growth of about 61.2% a year.

Net income in fiscal 2025 was -$1.3B, a net margin of -39.6%; the best year in this period was 2021 with $11.7B.

Over the twelve months to September 30, 2026, revenue was $2.7B and net income -$1.6B.

Free cash flow was $330M in fiscal 2025 and positive in 4 of the 9 years shown.

Revenue, profit and cash flow by year

Revenue
2017: $74M172018: $146M182019: $122M192020: $592M202021: $21.5B212022: $18.5B222023: $4.2B232024: $2.9B242025: $3.4B25$3.4B
Net income
2017: -$103M172018: -$55M182019: -$201M192020: $19M202021: $11.7B212022: $10.1B222023: $1.0B232024: -$691M242025: -$1.3B25-$1.3B
Free cash flow
2017: -$92M172018: -$102M182019: -$266M192020: -$98M202021: $863M212022: $14.1B222023: $5.7B232024: -$82M242025: $330M25$330M
EPS (diluted)
2017: $-0.41172018: $-0.22182019: $-0.80192020: $0.07202021: $46.41212022: $40.06222023: $4.09232024: $-2.75242025: $-5.3125$-5.31

Income statement

Fiscal yearTTM202520242023202220212020201920182017
Revenue$2.7B$3.4B$2.9B$4.2B$18.5B$21.5B$592M$122M$146M$74M
Gross profit—$2.6B$2.3B$3.6B$15.3B$18.2B$519M$102M$130M$63M
Operating income—-$1.7B-$1.4B$763M$13.5B$17.3B-$101M-$204M-$62M-$73M
Net income-$1.6B-$1.3B-$691M$1.0B$10.1B$11.7B$19M-$201M-$55M-$103M
EPS (diluted)$-6.49$-5.31$-2.75$4.09$40.06$46.41$0.07$-0.80$-0.22$-0.41
R&D——————————
Revenue growth—+18.0%−32.3%−77.1%−14.1%+3531.6%+385.1%−16.5%+97.7%—

Cash flow

Fiscal yearTTM202520242023202220212020201920182017
Operating cash flow-$254M$536M$216M$5.9B$14.5B$1.0B-$17M-$223M-$67M-$63M
Capital spending-$270M-$206M-$298M-$276M-$351M-$144M-$81M-$43M-$34M-$29M
Free cash flow-$524M$330M-$82M$5.7B$14.1B$863M-$98M-$266M-$102M-$92M
Dividends paid——$0$0$517M$0$0———
Buybacks——————————
Stock-based pay—$125M$105M$57M$116M$106M$39M$34M$9M$7M

Balance sheet

Fiscal yearTTM202520242023202220212020201920182017
Cash—$9.0B$10.1B$12.9B$14.8B$1.9B$1.5B$583M$471M$206M
Debt—————$341M$295M$83M——
Equity—$22.6B$20.2B$22.4B$21.4B$13.5B$1.7B$554M$305M-$58M
Total assets—$25.8B$23.4B$25.4B$24.8B$17.9B$2.8B$896M$748M—
Shares (diluted)250M251M251M251M251M251M251M251M251M251M

Margins and returns

Fiscal yearTTM202520242023202220212020201920182017
Gross margin—77.6%80.3%84.3%82.7%84.7%87.7%84.0%89.3%84.9%
Operating margin—-48.9%-47.8%18.1%73.0%80.5%-17.1%-167.1%-42.2%-99.5%
Net margin-60.9%-39.6%-24.2%24.4%54.5%54.2%3.1%-164.9%-37.6%-139.1%
FCF margin-19.7%9.8%-2.9%134.1%76.5%4.0%-16.5%-218.3%-69.6%-124.8%
ROIC—-5.8%-6.7%2.7%45.9%85.7%-4.0%-31.9%-16.0%—
ROE—-5.9%-3.4%4.6%47.0%86.5%1.1%-36.3%-18.0%177.7%

Frequently asked questions

What is BioNTech’s annual revenue?

$3.4B in fiscal 2025 and $2.7B over the twelve months to September 30, 2026.

How much profit does BioNTech make?

Net income was -$1.3B in fiscal 2025 (net margin -39.6%).

Is BioNTech’s revenue growing?

Yes: revenue rose 18.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.